



07-08-03

1642

EXPRESS MAILING LABEL NO. EV312365655US IN DATE: 07/07/2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Spencer FARR, et al.

Serial No.: 09/911,904

Group Art Unit: 1642

Filing Date: 07/23/2001

Examiner: Jeanine Anne Goldberg

For: Canine Toxicity Genes

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed please find the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO/SB/08a (2 sheets); and
3. Exhibits (12 enclosures).

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 18-1579. The Commissioner is also authorized to charge Deposit Account No. 18-1579 for any future fees connected in any way to this application. Two copies of this letter are enclosed.

Respectfully submitted,

John K. Abokhair, Esq.  
Registration No. 30,537  
Roberts Abokhair & Mardula, LLC  
11800 Sunrise Valley Drive, Suite 1000  
Reston, Virginia 20191  
(703) 391-2900

RECEIVED  
JUL 10 2003  
TECH CENTER 1600/2900



EXPRESS MAILING LABEL NO. EV312365655US IN DATE: 07/07/2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Spencer FARR, et al.

Serial No.: 09/911,904

Group Art Unit: 1642

Filing Date: 07/23/2001

Examiner:

Jeanine Anne Goldberg

For: Canine Toxicity Genes

\*\*\*\*\*  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97  
\*\*\*\*\*

RECEIVED  
JUL 10 2003  
TECH CENTER 1600/2900

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR §1.56, Applicant hereby submits the following Supplemental Information Disclosure Statement. The form PTO/SB/08a submitted lists references that were identified to Applicant after filing via an International Search Report from the International Searching Authority.

Pursuant to 37 CFR §1.97(e)(1), Applicant states that each item of information contained in the Supplemental Information Disclosure Statement was first cited in the International Search Report referenced above not more than three months prior to the filing herewith of the Supplemental Information Disclosure Statement. Because Applicant is submitting the Supplemental Information Disclosure Statement within the three-month deadline, no fee is required.

It is respectfully requested that the cited documents be considered by the Examiner, and that the Examiner indicate consideration of the cited references by returning copies of the attached form PTO/SB/08a with initials or other appropriate marks affixed. Copies of all references are enclosed.

Respectfully submitted,

John K. Abokhair, Esq.  
Registration No. 30,537  
Roberts Abokhair & Mardula, LLC  
11800 Sunrise Valley Drive, Suite 1000  
Reston, Virginia 20191  
(703) 391-2900

July 7, 2003

Atty. Docket No. 2874-002

**Express Mailing Label No. EV312365655US**

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**Complete if Known**

*(Use as many sheets as necessary)*

Sheet	01
-------	----

of 02

Application Number	09/911,904
Filing Date	07/23/2001
First Named Inventor	Spencer FARR, et al.
Art Unit	1642
Examiner Name	Jeanine Anne Goldberg
Attorney Docket Number	2874-002


[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	02	WO 00/12760	03/09/2000	Incyte Pharmaceuticals, Inc.		
	03	WO 99/05320	02/04/1999	Rapigene, Inc.		
	04	EP 0 292 879 A2	11/30/1988	Orion Corporation Ltd.		
	05	WO 01/51667 A2	07/19/2001	Integriderm, L.L.C.		

Date	
Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



IN DATE: 07/07/2003

Express Mailing Label No. EV312365655US

PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 02 of 02

**Complete if Known**

Application Number	09/911,904
Filing Date	07/23/2001
First Named Inventor	Spencer FARR, et al.
Art Unit	1642
Examiner Name	Jeanine Anne Goldberg
Attorney Docket Number	2874-002

RECEIVED  
JUL 10 2003  
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	06	KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.	
	07	BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.	
	08	SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8	
	09	FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology	
	10	MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11	
	11	SCHENA, et al., Parallel Human Genome Analysis: Microarray-based Expression Monitoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	
	12	Burczynski, et al., Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells, Toxicological Sciences, 2000, 399-415, Volume 58, Society of Toxicology	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.